Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Chronic Heart Failure

  Free Subscription

Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    February 2021
  1. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available

    December 2020
  2. RERICK L, Elston C, Kester J, Montepara C, et al
    Evaluation of sacubitril/valsartan initiation in outpatient heart failure patients.
    J Cardiovasc Pharmacol. 2020 Dec 1. doi: 10.1097/FJC.0000000000000966.
    PubMed     Abstract available

    November 2020
  3. WOHLFORD GF, Van Tassell BW, Billingsley HE, Kadariya D, et al
    A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000931.
    PubMed     Abstract available

  4. GAO D, David C, Rosa MM, Costa J, et al
    The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954.
    PubMed     Abstract available

  5. GIUSEPPE DEL BUONO M, Crea F, Versaci F, Biondi-Zoccai G, et al
    NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.
    J Cardiovasc Pharmacol. 2020 Nov 2. doi: 10.1097/FJC.0000000000000946.

    October 2020
  6. BERNIER TD, Buckley LF
    Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000929.
    PubMed     Abstract available

  7. HU J, Wu Y, Zhou X, Wang X, et al
    Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    J Cardiovasc Pharmacol. 2020;76:445-451.
    PubMed     Abstract available

    August 2020
  8. LI C, Xia W, Wang L, Zhang J, et al
    Effect of renal denervation on cardiac function and inflammatory factors in heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Aug 24. doi: 10.1097/FJC.0000000000000899.
    PubMed     Abstract available

    July 2020
  9. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available

  10. PAPP Z, Agostoni P, Alvarez J, Bettex D, et al
    Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    J Cardiovasc Pharmacol. 2020;76:4-22.
    PubMed     Abstract available

    June 2020
  11. SHEN JL, Xie XJ
    Insight into the Pro-inflammatory and Pro-Fibrotic Role of Macrophage in Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2020 Jun 4. doi: 10.1097/FJC.0000000000000858.
    PubMed     Abstract available

  12. DENG T, Wei Z, Gael A, Deng X, et al
    Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    J Cardiovasc Pharmacol. 2020;75:535-544.
    PubMed     Abstract available

    February 2020
  13. KELLY J, Cheng J, Malloy R, Lupi K, et al
    Comparison of positive inotropic agents in the management of acute decompensated heart failure.
    J Cardiovasc Pharmacol. 2020 Feb 20. doi: 10.1097/FJC.0000000000000811.
    PubMed     Abstract available

    January 2020
  14. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available

    December 2019
  15. LTEIF C, Arwood MJ, Kansal M, Cavallari LH, et al
    Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
    J Cardiovasc Pharmacol. 2019 Dec 31. doi: 10.1097/FJC.0000000000000779.
    PubMed     Abstract available

    November 2019
  16. DEL BUONO MG, Bonaventura A, Vecchie A, Wohlford GF, et al
    Sacubitril-Valsartan for the treatment of heart failure: Time for a paragon?
    J Cardiovasc Pharmacol. 2019 Nov 29. doi: 10.1097/FJC.0000000000000782.

    August 2019
    cGMP Signaling and Modulation in Heart Failure.
    J Cardiovasc Pharmacol. 2019 Aug 27. doi: 10.1097/FJC.0000000000000749.
    PubMed     Abstract available

    July 2019
  18. PREEDY MEJ, Baliga RS, Hobbs AJ
    Multiplicity of Nitric Oxide and Natriuretic Peptide Signalling in Heart Failure.
    J Cardiovasc Pharmacol. 2019 Jul 24. doi: 10.1097/FJC.0000000000000724.
    PubMed     Abstract available

  19. ZENG H, Chen JX
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000719.
    PubMed     Abstract available

  20. BONAVENTURA A, Wohlford GF, Vecchie A, Van Tassel BW, et al
    In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    J Cardiovasc Pharmacol. 2019;74:1-3.

    June 2019
  21. TOYODA S, Arikawa T, Inami S, Nishikawa R, et al
    Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED.
    J Cardiovasc Pharmacol. 2019;73:365-372.
    PubMed     Abstract available

    March 2019
  22. PINTO G, Tondi L, Gemma M, De Marco A, et al
    Real Life Indications to Sacubitril/Valsartan Treatment in Patients with Chronic Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2019 Mar 6. doi: 10.1097/FJC.0000000000000665.
    PubMed     Abstract available

    February 2019
  23. VICENT L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, et al
    Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
    J Cardiovasc Pharmacol. 2019;73:118-124.
    PubMed     Abstract available

    January 2019
  24. HERPAIN A, Bouchez S, Girardis M, Guarracino F, et al
    Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.
    J Cardiovasc Pharmacol. 2019;73:3-14.
    PubMed     Abstract available

    December 2018
  25. DU AX, Westerhout CM, McAlister FA, Shanks M, et al
    The Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice.
    J Cardiovasc Pharmacol. 2018 Dec 10. doi: 10.1097/FJC.0000000000000643.
    PubMed     Abstract available

    November 2018
  26. LEENEN FH, Ahmad M, Marc Y, Llorens-Cortes C, et al
    Specific Inhibition of Brain Angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2018 Nov 30. doi: 10.1097/FJC.0000000000000638.
    PubMed     Abstract available

    May 2018
    Ivabradine's Pleiotropic Profile: Can It Protect against Doxorubicin-Induced Heart Failure?
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000597.

  28. CHANG PC, Lu YY, Lee HL, Lin SF, et al
    Paradoxical Effects of Sodium-Calcium Exchanger Inhibition on Torsade de Pointes and Early Afterdepolarization in a Heart Failure Rabbit Model.
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000598.
    PubMed     Abstract available

    April 2018
  29. SALAH EM, Bastacky SI, Jackson EK, Tofovic SP, et al
    Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2018;71:205-214.
    PubMed     Abstract available

    November 2017
  30. COLE-JEFFREY CT, Pepine CJ, Katovich MJ, Grant MB, et al
    Beneficial Effects Of Angiotensin-(1-7) On Cd34 + Cells From Heart Failure Patients.
    J Cardiovasc Pharmacol. 2017 Nov 8. doi: 10.1097/FJC.0000000000000556.
    PubMed     Abstract available

    September 2017
  31. ABBATE A, Van Tassell BW
    Levosimendan in advanced heart failure: where do we stand?
    J Cardiovasc Pharmacol. 2017 Sep 25. doi: 10.1097/FJC.0000000000000539.

    August 2017
  32. ALTENBERGER J, Gustafsson F, Harjola VP, Karason K, et al
    Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications.
    J Cardiovasc Pharmacol. 2017 Aug 15. doi: 10.1097/FJC.0000000000000533.
    PubMed     Abstract available

    June 2017
  33. HANSEN MS, Andersen A, Holmboe S, Schultz JG, et al
    Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508.
    PubMed     Abstract available

    April 2017
  34. BEI WJ, Wang K, Li HL, Lin KY, et al
    Safe Hydration Volume to Prevent Contrast-Induced Acute Kidney Injury and Worsening Heart Failure in Patients with Heart Failure and Preserved Ejection Fraction Following Cardiac Catheterization.
    J Cardiovasc Pharmacol. 2017 Apr 27. doi: 10.1097/FJC.0000000000000502.
    PubMed     Abstract available

    February 2017
  35. KOLPAKOV MA, Tilley DG, Sabri A
    Galphaq Signaling in the Regulation of Autophagy and Heart Failure.
    J Cardiovasc Pharmacol. 2017 Feb 3. doi: 10.1097/FJC.0000000000000471.

  36. HU J, Sharifi-Sanjani M, Tofovic SP
    Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.
    J Cardiovasc Pharmacol. 2017;69:93-100.
    PubMed     Abstract available

    January 2017
  37. HOLMBOE S, Andersen A, Johnsen J, Nielsen JM, et al
    Inotropic Effects of Prostacyclins on the Right Ventricle Are Abolished in Isolated Rat Hearts With Right-Ventricular Hypertrophy and Failure.
    J Cardiovasc Pharmacol. 2017;69:1-12.
    PubMed     Abstract available

    April 2016
  38. HILLGAARD TK, Andersen A, Andersen S, Vildbrad MD, et al
    Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure.
    J Cardiovasc Pharmacol. 2016;67:275-82.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.